sal next-generation sequencing (NGS)-based oncology test system. In September 2014, Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. In September 2014, MannKind Corporation announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza(R) (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. In September 2014, Apollo Hospitals and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. In October 2014, Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. History The company was founded in 1970. It was formerly known as Sanofi-Aventis and changed its name to Sanofi in 2011.
sanofi-titr part10%87 (RHPP:EN Paris)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
|AbbVie Inc||$61.18 USD||+1.20|
|Amgen Inc||$161.58 USD||+2.70|
|Bayer AG||€110.42 EUR||+2.62|
|Bristol-Myers Squibb Co||$58.98 USD||+4.82|
|Novo Nordisk A/S||kr271.40 DKK||+15.90|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-TITR PART10%87, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.